Kodiak Sciences to Present Clinical Trial Results for Inflammatory Macular Edema Treatment

Kodiak Sciences plans to present new clinical data for its drug candidate, KSI-101, targeting macular edema secondary to inflammation. These findings will be shared at upcoming scientific meetings. The reported results from a tertiary care setting are consistent with earlier Phase 1b study outcomes, supporting the ongoing global development of the treatment.